While purchasing medicine - It is important that you let us know what other medicine you are using.
This is for preventing unwanted drug interactions.


Want to ask us a professional question ? Call us or Connect VIA Skype





Skype Me™! 
 



 
 
 
 

EPIRUBICIN EBEWE
Home >> Search Drug By Letter >> Search Drug By Letter: E >> EPIRUBICIN EBEWE
Search Drug By Letter : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

EPIRUBICIN EBEWE
 
Package(a):
VIALS: 1 x 10 mg/5 ml.
Dosage(a):
I.V./intravesical use: The dosage should be adjusted according to the indication, age, general condition, cardiac or hepatic function and concurrent chemotherapy and blood counts. See prescribing information for full details.
Prescribing Restrictions:  None

Package(b):
VIALS: 1 x 50 mg/25 ml.
Dosage(b):
I.V./intravesical use: The dosage should be adjusted according to the indication, age, general condition, cardiac or hepatic function and concurrent chemotherapy and blood counts. See prescribing information for full details.
Prescribing Restrictions:  None

Package(c):
VIALS: 1 x 100 mg/50 ml.
Dosage(c):
I.V./intravesical use: The dosage should be adjusted according to the indication, age, general condition, cardiac or hepatic function and concurrent chemotherapy and blood counts. See prescribing information for full details.
Prescribing Restrictions:  None


Indications:
For the treatment of a wide spectrum of neoplastic diseases, including breast carcinoma, lung carcinoma (high doses), ovarian carcinoma, gastric carcinomas, soft tissue sarcoma. Intravesical administration has been found to be beneficial in the treatment of superficial bladder carcinomas and in the prophylaxis of recurrences after transurethral resection. I.V. administration of the treatment of advanced bladder carcinoma.
Contra-Indications:
By I.V. route: Known hypersensitivity to epirubicin. Severe bone marrow depression following previous chemotherapy and/or radiotherapy. Patients already treated with anthracyclines such as doxorubicin or daunorubicin up to the relevant maximum cumulative dose. Acute infections and existing inflammation of the buccal and/or G.I. mucosa. Progressive heart failure, arrhythmia and conductive disorders with serious hemodynamic effects, acute inflammatory myocardial conditions, unstable angina pectoris, acute myocardial infarction or myocardial infarction within previous 6 months, cardiomyopathy. 
By intravesical route: Should not be given by intravesical instillation for the treatment of invasive tumors penetrating the bladder wall.
Special Precautions:
See prescribing information for full details.
Side Effects:
Myelosuppression and cardiotoxicity, nausea, vomiting and mucositis, reversible alopecia. See prescribing information for full details.
Drug Interactions:
Heparin, anticytostatic agents, alkaline solutions.